RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Addex Therapeutics Stock

Addex Therapeutics ROA 2025

Addex Therapeutics ROA

0.66

Ticker

ADXN.SW

ISIN

CH0029850754

WKN

A0MSH6

In 2025, Addex Therapeutics's return on assets (ROA) was 0.66, a -129.06% increase from the -2.27 ROA in the previous year.

Addex Therapeutics Aktienanalyse

What does Addex Therapeutics do?

Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Addex Therapeutics's Return on Assets (ROA)

Addex Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Addex Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Addex Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Addex Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Addex Therapeutics stock

What is the Return on Assets (ROA) of Addex Therapeutics this year?

The Return on Assets (ROA) of Addex Therapeutics is 0.66 undefined this year.

What was the ROA of Addex Therapeutics compared to the previous year?

The ROA of Addex Therapeutics has increased by -129.06% compared to the previous year.

What consequences do high ROA have for investors of Addex Therapeutics?

A high ROA is advantageous for investors of Addex Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Addex Therapeutics?

A low ROA can be unfavorable for investors of Addex Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Addex Therapeutics affect the company?

An increase in ROA of Addex Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Addex Therapeutics impact the company?

A reduction in the ROA of Addex Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Addex Therapeutics?

Some factors that can influence the ROA of Addex Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Addex Therapeutics important for investors?

The ROA of Addex Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Addex Therapeutics take to improve ROA?

To improve ROA, Addex Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Addex Therapeutics pay?

Over the past 12 months, Addex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Addex Therapeutics is expected to pay a dividend of 0 CHF.

What is the dividend yield of Addex Therapeutics?

The current dividend yield of Addex Therapeutics is .

When does Addex Therapeutics pay dividends?

Addex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Addex Therapeutics?

Addex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Addex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Addex Therapeutics located?

Addex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Addex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Addex Therapeutics from 8/22/2025 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 8/22/2025.

When did Addex Therapeutics pay the last dividend?

The last dividend was paid out on 8/22/2025.

What was the dividend of Addex Therapeutics in the year 2024?

In the year 2024, Addex Therapeutics distributed 0 CHF as dividends.

In which currency does Addex Therapeutics pay out the dividend?

The dividends of Addex Therapeutics are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Addex Therapeutics

Our stock analysis for Addex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.